<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Prospective Grant of Exclusive License: The Development of Human Anti-CD22 Monoclonal Antibodies for the Treatment of Human Cancers and Autoimmune Disease</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Prospective Grant of Exclusive License: The Development of Human Anti-CD22 Monoclonal Antibodies for the Treatment of Human Cancers and Autoimmune Disease</h1>
    <p class="timestamp">Published: 2012-02-17 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in U.S. Patent Application 61/042,239 entitled "Human Monoclonal Antibodies Specific for CD22" [HHS Ref. E-080-2008/0-US-01], PCT Application PCT/US2009/124109 entitled "Human and Improved Murine Monoclonal Antibodies Against CD22" ...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, National Institutes of Health</p>
    <p><strong>Document Number:</strong> 2012-3829</p>
    <p><strong>Publication Date:</strong> 2012-02-17</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2012/02/17/2012-3829/prospective-grant-of-exclusive-license-the-development-of-human-anti-cd22-monoclonal-antibodies-for">https://www.federalregister.gov/documents/2012/02/17/2012-3829/prospective-grant-of-exclusive-license-the-development-of-human-anti-cd22-monoclonal-antibodies-for</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2012-3829</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
